Obsidian Therapeutics is thrilled to announce the successful raising of $160 million in a recent funding round, a significant milestone that underscores our commitment to pioneering advancements in controllable cell and gene therapies. Our mission at Obsidian is clear: to deliver transformative outcomes for patients grappling with intractable diseases. Leveraging our cutting-edge cytoDriveâ„¢ technology, we are developing innovative cell and gene therapy products designed to precisely control protein expression, thereby enhancing therapeutic efficacy. Our flagship program, cytoTIL15, focuses on engineering tumor-infiltrating lymphocytes (TILs) to improve their effectiveness across a broader patient population, paving the way for new treatment options where none existed before.
This funding comes from a consortium of blue-chip investors who share our vision, coupled with the guidance of field-leading advisors and collaborations with industry titans. It enables us to expand our team, further our research efforts, and accelerate the development of our promising therapies in areas of urgent clinical need. Based in the thriving biotechnology hub of Cambridge, complemented by our new lab facility in Bedford, Obsidian Therapeutics is not just about innovation; we are dedicated to fostering a diverse and inclusive workplace where every 'Obsidianite' feels a sense of belonging and is empowered to contribute their best work. As we move forward with this phenomenal backing, we are excited about the opportunities ahead to redefine treatment paradigms and ultimately bring hope to patients and families in need.
